Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment
- 233 Downloads
Epithelioid hemangioendothelioma (EHE) is an extremely rare sarcoma, as such it can pose a clinical dilemma based solely on its rarity. Also, the spectrum of disease varies greatly between an indolent disease and aggressive disease with widespread metastases. In our clinical practice, the primary focus has been to get a handle on the aggressive nature of the disease, which will then dictate how urgently one needs to treat the patient. Pathological review with immunohistochemistry and molecular characterization is paramount. Our treatment strategy is watch-and-wait versus active therapy on clinical trial or based on results of prior clinical trials. There is evidence to support the use of chemotherapeutics and targeted therapies specifically focusing on anti-angiogenesis. The current landscape of oncology with the emergence and excitement of immunotherapy could also translate in a role for immunotherapy in this disease. While rare, there is certainly no reason that research and trials for patients with EHE should not remain on utmost importance for those of us who specialize in the treatment of sarcomas.
KeywordsEpithelioid hemangioendothelioma Sarcoma WWTR1 CAMTA1
Compliance with Ethical Standards
Conflict of Interest
Ari Rosenberg and Mark Agulnik declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance
- 19.•• Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol. 2015;39(1):132–9. This large series which included 52 patients help us better understand the pathology and molecular profile of these rare tumorsPubMedPubMedCentralCrossRefGoogle Scholar
- 24.Thway K, Mentzel T, Perrett CM, Calonje E. Multicentric visceral epithelioid hemangioendothelioma, with extremity dermal deposits, unusual late recurrence on the nasal bridge and TFE3 gene rearrangement. Hum Pathol 2017.Google Scholar
- 44.• Semenisty V, Naroditsky I, Keidar Z, Bar-Sela G. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options. BMC Cancer. 2015;15:402. Although only a case report, this paper provides a review of antiangiogenic agents for the treatment of this diseasePubMedPubMedCentralCrossRefGoogle Scholar
- 48.Fang C, Zhang W, Zheng S. Liver transplantation for hepatic epithelioidhemangioendothelioma: a casereport and literature review. Int J Clin Exp Med. 2017;10(6):9693–6.Google Scholar
- 49.Saste A, Cabrera Fernandez DF, Gulati R, Gamalski S. A trimodality approach in the management of metastatic low-grade epithelioid hemangioendothelioma of the bone. BMJ Case Rep 2015;2015.Google Scholar